Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster … (NCT05894395) | Clinical Trial Compass
UnknownPhase 3
Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination
Switzerland200 participantsStarted 2023-12-01
Plain-language summary
The purpose of this study is to investigate the immunity of persons fully vaccinated against measles, mumps and rubella and to examine the course of immunity after booster vaccination.
Who can participate
Age range18 Years – 49 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 18-49 (inclusive) at the time of the study screening visit
* Has received exactly two previous doses of MMR-containing vaccine at any point up to one calendar year prior to the study screening visit
* Willing to receive a booster MMR vaccination as outlined in the study protocol
* Able and willing to comply with all other study requirements (attend all study visits and provide blood, saliva, nasal wash samples at each visit as outlined)
* Sufficient language (German or English) and cognitive skills
* Provides written, informed consent to participate in the study
Exclusion Criteria:
* Acute respiratory or other infections (postpone baseline visit until resolved)
* Receipt of any other vaccination less than 4 weeks prior to the baseline visit or intention to receive another vaccination within 4 weeks following the baseline visit
* Previous hypersensitivity reaction following receipt of any MMR-containing vaccine or previous hypersensitivity reaction to any component of M-M-R-vaxPro
* Pregnancy, lactation, or intention to become pregnant during the study
* Individuals with confirmed or suspected immunosuppressive or immune-deficient state
* Known current or chronic or severe disease
* Receipt of blood or plasma transfusions, or administration of immune globulin (IG) less than 12 weeks prior to the baseline visit, or intention to receive IG within 4 weeks following the baseline visit
* Any other significant disease, disorder, or finding which could p…
What they're measuring
1
Immunogenicity post MMR-booster vaccination
Timeframe: From admission to one year post vaccination